TNSN03141A1 - Formulation pharmaceutique au gout masque et son procede de preparation - Google Patents

Formulation pharmaceutique au gout masque et son procede de preparation

Info

Publication number
TNSN03141A1
TNSN03141A1 TNPCT/FR2002/002158A TNSN03141A TNSN03141A1 TN SN03141 A1 TNSN03141 A1 TN SN03141A1 TN SN03141 A TNSN03141 A TN SN03141A TN SN03141 A1 TNSN03141 A1 TN SN03141A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical formulation
mask taste
taste
aqueous suspension
Prior art date
Application number
TNPCT/FR2002/002158A
Other languages
English (en)
French (fr)
Inventor
Becourt Philippe
Schwabe Detlev
Chauvin Josiane
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TNSN03141A1 publication Critical patent/TNSN03141A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TNPCT/FR2002/002158A 2001-06-21 2002-06-21 Formulation pharmaceutique au gout masque et son procede de preparation TNSN03141A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0108157A FR2826274B1 (fr) 2001-06-21 2001-06-21 Formulation pharmaceutique au gout masque et son procede de preparation

Publications (1)

Publication Number Publication Date
TNSN03141A1 true TNSN03141A1 (fr) 2005-12-23

Family

ID=8864587

Family Applications (1)

Application Number Title Priority Date Filing Date
TNPCT/FR2002/002158A TNSN03141A1 (fr) 2001-06-21 2002-06-21 Formulation pharmaceutique au gout masque et son procede de preparation

Country Status (41)

Country Link
US (2) US7138138B2 (enExample)
EP (1) EP1401397B1 (enExample)
JP (1) JP4880871B2 (enExample)
CN (1) CN1239149C (enExample)
AP (1) AP1595A (enExample)
AR (1) AR036096A1 (enExample)
AT (1) ATE290366T1 (enExample)
AU (1) AU2002329311B2 (enExample)
BG (1) BG66314B1 (enExample)
BR (1) BRPI0208998A2 (enExample)
CA (1) CA2452239C (enExample)
CO (1) CO5540278A2 (enExample)
CZ (1) CZ299947B6 (enExample)
DE (1) DE60203178T2 (enExample)
EA (1) EA006016B1 (enExample)
EC (1) ECSP034915A (enExample)
ES (1) ES2236574T3 (enExample)
FR (1) FR2826274B1 (enExample)
GT (2) GT200200115AA (enExample)
HR (1) HRP20031067B1 (enExample)
HU (1) HUP0400799A3 (enExample)
IL (2) IL159404A0 (enExample)
JO (1) JO2325B1 (enExample)
MA (1) MA27042A1 (enExample)
MX (1) MXPA03011756A (enExample)
MY (1) MY134340A (enExample)
NO (1) NO332258B1 (enExample)
NZ (1) NZ530042A (enExample)
OA (1) OA12635A (enExample)
PA (1) PA8548301A1 (enExample)
PE (1) PE20030201A1 (enExample)
PL (1) PL202090B1 (enExample)
PT (1) PT1401397E (enExample)
SK (1) SK285865B6 (enExample)
SV (1) SV2003001098A (enExample)
TN (1) TNSN03141A1 (enExample)
TW (1) TWI228049B (enExample)
UA (1) UA77960C2 (enExample)
UY (1) UY27341A1 (enExample)
WO (1) WO2003000225A2 (enExample)
ZA (1) ZA200309479B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
GB2419094A (en) 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
FR2882522B1 (fr) * 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20060264386A1 (en) * 2005-05-17 2006-11-23 Rongqi Sun Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof
CN101370480A (zh) * 2006-02-03 2009-02-18 赢创罗姆有限责任公司 含有由聚合物和在水中溶解较差的活性成分组成的混合物的药物组合物
WO2007108010A2 (en) * 2006-03-21 2007-09-27 Jubilant Organosys Limited Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
KR100935893B1 (ko) * 2007-09-11 2010-01-07 국방과학연구소 1,1'-다이메틸-5,5’-바이테트라졸의 합성방법
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EA021761B9 (ru) 2008-12-16 2015-12-30 Карлсберг А/С Полимерный материал на основе целлюлозы
CN104470527B (zh) 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
DE102012014848A1 (de) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Heilerde-Zubereitung
BR112017002335A2 (pt) * 2014-08-05 2018-01-16 Cempra Pharmaceuticals, Inc. formulações de suspensão oral em pó de agentes antibacterianos
US10982177B2 (en) 2017-09-18 2021-04-20 The Clorox Company Cleaning wipes with particular lotion retention and efficacy characteristics
CN114209661B (zh) * 2022-02-21 2022-04-29 北京罗诺强施医药技术研发中心有限公司 呈细粒形式的固体药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930409A1 (de) * 1979-07-26 1981-02-12 Bayer Ag Spruehtrocknung von mikrokapseldispersionen
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
EP1027036A2 (en) * 1997-10-03 2000-08-16 ELAN CORPORATION, Plc Taste masked formulations
IN191239B (enExample) * 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
EP1313751B1 (en) * 2000-08-22 2008-09-17 Basilea Pharmaceutica AG New macrolides with antibacterial activity

Also Published As

Publication number Publication date
ZA200309479B (en) 2005-04-26
DE60203178D1 (de) 2005-04-14
FR2826274B1 (fr) 2003-09-26
OA12635A (fr) 2006-06-15
US20070014857A1 (en) 2007-01-18
NZ530042A (en) 2005-09-30
JP2004534810A (ja) 2004-11-18
HK1067558A1 (en) 2005-04-15
EA200400061A1 (ru) 2004-06-24
JP4880871B2 (ja) 2012-02-22
US20040142029A1 (en) 2004-07-22
BG66314B1 (bg) 2013-04-30
HUP0400799A3 (en) 2012-08-28
HUP0400799A2 (hu) 2004-08-30
EP1401397B1 (fr) 2005-03-09
CZ299947B6 (cs) 2009-01-07
AP1595A (en) 2006-04-12
CA2452239A1 (fr) 2003-01-03
ES2236574T3 (es) 2005-07-16
AR036096A1 (es) 2004-08-11
CN1239149C (zh) 2006-02-01
MY134340A (en) 2007-12-31
BG108458A (bg) 2005-02-28
SV2003001098A (es) 2003-03-18
IL159404A (en) 2007-08-19
CN1529585A (zh) 2004-09-15
PA8548301A1 (es) 2003-09-05
GT200200115A (es) 2003-02-27
ATE290366T1 (de) 2005-03-15
DE60203178T2 (de) 2006-01-26
CZ20033441A3 (en) 2004-03-17
WO2003000225A3 (fr) 2003-03-13
AU2002329311B2 (en) 2007-02-01
PL366803A1 (en) 2005-02-07
AP2003002927A0 (en) 2003-12-31
JO2325B1 (en) 2006-06-28
CA2452239C (fr) 2011-07-19
IL159404A0 (en) 2004-06-01
FR2826274A1 (fr) 2002-12-27
UA77960C2 (en) 2007-02-15
BRPI0208998A2 (pt) 2017-06-06
EA006016B1 (ru) 2005-08-25
MA27042A1 (fr) 2004-12-20
MXPA03011756A (es) 2004-07-01
GT200200115AA (es) 2005-01-12
PL202090B1 (pl) 2009-06-30
SK285865B6 (sk) 2007-10-04
PT1401397E (pt) 2005-05-31
TWI228049B (en) 2005-02-21
HRP20031067A2 (en) 2004-04-30
NO332258B1 (no) 2012-08-13
ECSP034915A (es) 2004-02-26
CO5540278A2 (es) 2005-07-29
UY27341A1 (es) 2003-01-31
PE20030201A1 (es) 2003-03-12
NO20035581D0 (no) 2003-12-15
SK15922003A3 (sk) 2004-05-04
WO2003000225A2 (fr) 2003-01-03
EP1401397A2 (fr) 2004-03-31
US7138138B2 (en) 2006-11-21
HRP20031067B1 (en) 2011-10-31

Similar Documents

Publication Publication Date Title
Li et al. Nano–bio interactions: biofilm‐targeted antibacterial nanomaterials
MA28740B1 (fr) Methodes de traitement d'infections endobronchiques
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
CA2401910A1 (en) Hydrophilic molecular disperse solutions of carvedilol
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
NZ709754A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
DE69011766D1 (de) Wässerige Arzneisuspension für im wesentlichen wasserunlösliche Arzneiwirkstoffe.
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
JO2325B1 (en) A pharmaceutical composition with a flavoring taste and a process to prepare it
TNSN03106A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuse uniforme
MXPA04009412A (es) Metodos neuroprotectores, composiciones y metodos para seleccion de los mismos.
EP1852114A4 (en) COMPOSITION WITH DIHOMO (GAMMA) LINE ACIDIC ACID (DGLA) AS AN ACTIVE INGREDIENTS
JP5715139B2 (ja) 消化管に存在する望ましくない分子を特異的に吸着し得る医学製剤
ATE390127T1 (de) Universelle zusammensetzung zur kontrollierten wirkstoffabgabe enthaltend chitosan
WO2021244481A1 (en) Compositions and methods for treating a sars-cov-2 infection
RU96120655A (ru) Композиция для профилактики и лечения гриппа и орви
NO940064L (no) Öyepreparat på polyakrylsyrebasis
US7153526B2 (en) Treatment of gastrointestinal infections
WO2003105811A3 (en) Controlled release compositions and methods for using same
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use
NO20010507L (no) Farmasoytisk sammensetning med antitumoraktivitet pa basis av karboplatin
EP4225277B1 (en) Mesoporous nanoparticle system to increase the biofilm eradication activity by means of the carrying and the administration of at least one active ingredient and related production method
WO2000025765A3 (de) Wässrige arzneimittelformulierung zur oralen applikation
ZA200705660B (en) Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate